U.S. Stock Market News | Stocks related to weight loss drugs fell, Novo Nordisk dropped more than 4%
On Wednesday, stocks related to the weight loss drug concept fell. As of the time of publication, Novo Nordisk fell by over 4%, Eli Lilly fell by 1.6%, and Pfizer fell by 0.34%. Analysis by doctors at Massachusetts Eye and Ear, an affiliate of Harvard Medical School, suggests that Novo Nordisk's popular weight loss drugs Ozempic and Wegovy may be associated with an increased risk of rare vision loss. Research based on medical records shows that patients using Novo Nordisk's weight loss drugs to lose weight are seven times more likely to develop non-arteritic anterior ischemic optic neuropathy (NAION) compared to those using other brands of weight loss drugs
According to the information from Zhitong Finance APP, on Wednesday, stocks related to weight loss drugs fell. As of the time of publication, Novo Nordisk (NVO.US) dropped more than 4%, Eli Lilly (LLY.US) fell 1.6%, and Pfizer (PFE.US) fell 0.34%. Analysis by doctors at Massachusetts Eye and Ear, an affiliate of Harvard Medical School, showed that Novo Nordisk's popular weight loss drugs Ozempic and Wegovy appear to be associated with an increased risk of rare vision loss. Research on medical records showed that patients using Novo Nordisk's weight loss drugs to lose weight were seven times more likely to develop non-arteritic anterior ischemic optic neuropathy (NAION) compared to those using other brands of weight loss drugs